Update
$Dare Bioscience (DARE.US)$ Daré Bioscience Announces Publication In The Journal Of Sexual Medicine Of Findings From The Phase 2b RESPOND Clinical Study Of Sildenafil Cream, 3.6%
Benzinga· 4 mins ago
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies
Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance
Benzinga· 4 mins ago
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that either method could be used to assess treatment efficacy in future clinical studies
Longer recall intervals for PRO assessments are less burdensome to clinical study participants and may improve data collection compliance
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
